TapewireFind a company

person · Reporting owner

Huntsman Carole

Disclosed activity across 1 company

Tapewire entity
62345
SEC CIK
0002001571

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441Chief Commercial OfficerMarch 04, 2026March 06, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

MADRIGAL PHARMACEUTICALS, INC.

Report date March 04, 2026 · Filed March 06, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect12,692 Ending reported balance After 2026-03-06 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-03-04 · Grant · Acquired 3,989 · Balance 13,111

F1: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date.

Row 2 · 2026-03-06 · Sale · Disposed 419 · Balance 12,692

F2: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $434.80 · Expires 2036-03-04Direct4,986 Reported balance After 2026-03-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-03-04 · Grant · Acquired 4,986 · Balance 4,986

F3: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date.

F2: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

F3: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 06, 2026 Filed Mar 6, 2026 23:15 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 419 $431.94 $180,982.86
Disclosure

SEC source: 0001628280-26-015758 · wk-form4_1772838950.xml · nonDerivative · entry 2

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,692

F2 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

Read SEC document
March 04, 2026 Filed Mar 6, 2026 23:15 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 GrantStock Option (Right to Buy) · Derivative 4,986 $0.00 Strike: $434.80 $0.00
Disclosure

SEC source: 0001628280-26-015758 · wk-form4_1772838950.xml · derivative · entry 3

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,986

Underlying: Common Stock · 4,986 shares

Expires 2036-03-04

F3 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

Read SEC document
March 04, 2026 Filed Mar 6, 2026 23:15 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 GrantCommon Stock 3,989 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-015758 · wk-form4_1772838950.xml · nonDerivative · entry 1

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,111

F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date.

Read SEC document
January 26, 2026 Filed Jan 26, 2026 22:38 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 570 $494.59 $281,916.30
Disclosure

SEC source: 0001628280-26-003482 · wk-form4_1769467117.xml · nonDerivative · entry 2

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,122

F2 · kind: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

Read SEC document
January 26, 2026 Filed Jan 26, 2026 22:38 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 340 $492.42 $167,422.80
Disclosure

SEC source: 0001628280-26-003482 · wk-form4_1769467117.xml · nonDerivative · entry 1

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,692

F1 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

Read SEC document
November 21, 2025 Filed Nov 21, 2025 22:39 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 80 $564.57 $45,165.20
Disclosure

SEC source: 0001628280-25-053648 · wk-form4_1763764773.xml · nonDerivative · entry 11

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,032

F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $564.55 to $564.58, inclusive.

Read SEC document
November 21, 2025 Filed Nov 21, 2025 22:39 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 40 $563.21 $22,528.40
Disclosure

SEC source: 0001628280-25-053648 · wk-form4_1763764773.xml · nonDerivative · entry 10

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,112

F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

Read SEC document
November 21, 2025 Filed Nov 21, 2025 22:39 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 80 $560.62 $44,849.60
Disclosure

SEC source: 0001628280-25-053648 · wk-form4_1763764773.xml · nonDerivative · entry 9

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,152

F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $560.24 to $561.00, inclusive.

Read SEC document
November 21, 2025 Filed Nov 21, 2025 22:39 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 200 $559.60 $111,919.60
Disclosure

SEC source: 0001628280-25-053648 · wk-form4_1763764773.xml · nonDerivative · entry 8

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,232

F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $559.22 to $560.06, inclusive.

Read SEC document
November 21, 2025 Filed Nov 21, 2025 22:39 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 120 $556.04 $66,724.80
Disclosure

SEC source: 0001628280-25-053648 · wk-form4_1763764773.xml · nonDerivative · entry 7

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,432

F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $555.74 to $556.19, inclusive.

Read SEC document
November 21, 2025 Filed Nov 21, 2025 22:39 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 40 $553.23 $22,129.13
Disclosure

SEC source: 0001628280-25-053648 · wk-form4_1763764773.xml · nonDerivative · entry 6

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,552

F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $553.22 to $553.23, inclusive.

Read SEC document
November 21, 2025 Filed Nov 21, 2025 22:39 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 200 $552.38 $110,476.80
Disclosure

SEC source: 0001628280-25-053648 · wk-form4_1763764773.xml · nonDerivative · entry 5

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,592

F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $551.96 to $552.81, inclusive.

Read SEC document
November 21, 2025 Filed Nov 21, 2025 22:39 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 40 $549.34 $21,973.70
Disclosure

SEC source: 0001628280-25-053648 · wk-form4_1763764773.xml · nonDerivative · entry 4

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,792

F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $549.30 to $549.38, inclusive.

Read SEC document
November 21, 2025 Filed Nov 21, 2025 22:39 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 120 $548.71 $65,845.20
Disclosure

SEC source: 0001628280-25-053648 · wk-form4_1763764773.xml · nonDerivative · entry 3

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,832

F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $548.25 to $548.94, inclusive.

Read SEC document
November 21, 2025 Filed Nov 21, 2025 22:39 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 144 $547.27 $78,806.64
Disclosure

SEC source: 0001628280-25-053648 · wk-form4_1763764773.xml · nonDerivative · entry 2

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,952

F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $547.12 to $547.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

Read SEC document
November 21, 2025 Filed Nov 21, 2025 22:39 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 894 $550.97 $492,567.18
Disclosure

SEC source: 0001628280-25-053648 · wk-form4_1763764773.xml · nonDerivative · entry 1

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,096

F1 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

Read SEC document
March 05, 2025 Filed Mar 7, 2025 21:31 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 GrantStock Option (Right to Buy) · Derivative 5,703 $0.00 Strike: $347.28 $0.00
Disclosure

SEC source: 0001628280-25-011321 · wk-form4_1741383098.xml · derivative · entry 2

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,703

Underlying: Common Stock · 5,703 shares

Expires 2035-03-05

F2 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 5, 2026) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

Read SEC document
March 05, 2025 Filed Mar 7, 2025 21:31 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 GrantCommon Stock 3,386 $0.00 $0.00
Disclosure

SEC source: 0001628280-25-011321 · wk-form4_1741383098.xml · nonDerivative · entry 1

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,990

F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029, provided the Reporting Person continues in service with the Issuer on each such date.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:24 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 563 $335.00 $188,605.00
Disclosure

SEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 9

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,604

F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:24 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 100 $329.64 $32,964.00
Disclosure

SEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 8

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,167

F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:24 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 100 $327.49 $32,749.00
Disclosure

SEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 7

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,267

F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:24 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 100 $326.34 $32,634.00
Disclosure

SEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 6

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,367

F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:24 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 200 $324.59 $64,918.00
Disclosure

SEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 5

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,467

F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $324.48 to $324.70, inclusive.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:24 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 200 $323.65 $64,730.00
Disclosure

SEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 4

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,667

F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $323.47 to $323.83, inclusive.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:24 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 300 $320.21 $96,063.00
Disclosure

SEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 3

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,867

F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $320.13 to $320.32, inclusive.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:24 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 200 $314.74 $62,948.00
Disclosure

SEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 2

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,167

F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $314.40 to $315.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:24 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 71 $313.08 $22,228.68
Disclosure

SEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 1

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,367

F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

Read SEC document
January 24, 2025 Filed Jan 27, 2025 22:18 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 347 $335.24 $116,328.28
Disclosure

SEC source: 0001628280-25-002680 · wk-form4_1738016309.xml · nonDerivative · entry 1

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,438

F1 · kind: The sale reported on this Form 4 represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

Read SEC document
November 21, 2024 Filed Nov 22, 2024 21:30 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 SaleCommon Stock 688 $316.92 $218,040.96
Disclosure

SEC source: 0000950170-24-130239 · ownership.xml · nonDerivative · entry 1

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,785

F1 · kind: The sale reported on this Form 4 represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

Read SEC document
January 23, 2024 Filed Jan 25, 2024 23:04 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 GrantMarket Stock Unit · Derivative 3,639 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-007572 · ownership.xml · derivative · entry 3

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,639

Underlying: Common Stock · 3,639 shares

Expires not disclosed

F3 · derivative.exercise_price: Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026.

F3 · derivative.exercise_date: Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026.

F3 · derivative.expiration_date: Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026.

Read SEC document
January 23, 2024 Filed Jan 25, 2024 23:04 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 GrantStock Option (Right to Buy) · Derivative 5,483 $0.00 Strike: $229.00 $0.00
Disclosure

SEC source: 0000950170-24-007572 · ownership.xml · derivative · entry 2

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,483

Underlying: Common Stock · 5,483 shares

Expires 2031-01-23

F2 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (January 23, 2025) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.

Read SEC document
January 23, 2024 Filed Jan 25, 2024 23:04 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 GrantCommon Stock 3,639 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-007572 · ownership.xml · nonDerivative · entry 1

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,473

F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 23, 2025, January 23, 2026, January 23, 2027 and January 23, 2028, provided the Reporting Person continues in service with the Issuer on each such date.

Read SEC document
November 20, 2023 Filed Nov 22, 2023 22:02 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 GrantStock Option (Right to Buy) · Derivative 10,077 $0.00 Strike: $190.05 $0.00
Disclosure

SEC source: 0000950170-23-065902 · ownership.xml · derivative · entry 2

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,077

Underlying: Common Stock · 10,077 shares

Expires 2033-11-20

F2 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (November 20, 2024) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.

Read SEC document
November 20, 2023 Filed Nov 22, 2023 22:02 UTC MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 GrantCommon Stock 7,834 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-065902 · ownership.xml · nonDerivative · entry 1

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,834

F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of November 20, 2024, November 20, 2025, November 20, 2026 and November 20, 2027, provided the Reporting Person continues in service with the Issuer on each such date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.